DUBLIN–(BUSINESS WIRE)–The “Artificial Intelligence-enabled Drug Discovery, 2022: Frost Radar Report” report has been added to ResearchAndMarkets.com’s offering.
This report presents competitive profiles on each of the companies based on their strengths, opportunities, and a small discussion on their positioning.
The report finds that the impact of AI on the entire pharma value chain can more than double what is achievable using traditional analytics and capture between 2% and 3% of industry revenue, amounting to more than $50 billion in potential annual impact.
Pharmaceutical drug discovery and development has been suffering from declining success rates with new molecules primarily because of poor external validity of preclinical models and lack of efficacy of the molecule in terms of the intended disease indication.
Drug success rates continue to be in the range of only 1 in 10 that enters clinical phases pushing through to FDA approval. Frost & Sullivan finds that traditional solutions focused primarily on data from limited sources and rule-based computational techniques used to address the understanding of targets and leads are inefficient.
Artificial intelligence (AI) is set to transform the drug discovery landscape. AI-based products and solutions are transforming drug discovery and development dynamics by enabling pharmaceutical players to shorten discovery timelines, enhance process agility, increase prediction accuracy on efficacy and safety, and improve the opportunity to diversify drug pipelines using a cost-effective model.
Most pharmaceutical vendors are focused on collecting, creating, and augmenting data from across laboratories, clinical trials, real-world evidence, biobanks, and repositories. The increasing volume and veracity of clinical and research data is compelling traditional providers to leverage enabling tools and technologies such as cloud computing, AI and machine learning, natural language processing, and advanced analytics to make a shift to a relatively fast, rational data-driven drug discovery and development approach.
To remain competitive, companies must strike the right balance of data, AI, and computational capability and match it with the wet lab capability. There remains inadequate understanding of the biological networks and drug-target interactions. Enter AI, which has been able to support the identification and prioritization of disease-specific therapeutic targets based on gene-disease associations. Such results must be replicated and validated through in vitro experiments and in vivo models.
Key Topics Covered:
1. Strategic Imperative and Growth Environment
- Strategic Imperative
- Growth Environment
2. Frost Radar
- AI-enabled Drug Discovery
- Competitive Environment
3. Companies to Action
- AbCellera Biologics
- Atomwise
- BenevolentAI
- Berg Health
- Black Diamond Therapeutics
- Deep Genomics
- Evaxion Biotech
- Exscientia
- Generate Biomedicines
- GritstoneBio
- Healx
- Insilico Medicine
- Insitro
- Neumora Therapeutics
- Recursion
- Relay Therapeutics
- Schrodinger
- Valo Health
- XtalPi
4. Strategic Insights
5. Next Steps
For more information about this report visit https://www.researchandmarkets.com/r/h6d2f7
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900